Date | Price Target | Rating | Analyst |
---|---|---|---|
8/14/2024 | $24.00 | Neutral → Buy | H.C. Wainwright |
12/3/2021 | $6.00 | Buy | H.C. Wainwright |
9/22/2021 | $9.00 → $8.00 | Buy | Aegis Capital |
9/22/2021 | $6.25 | Buy → Strong Buy | WBB Securities |
9/22/2021 | Buy → Strong Buy | WBB Securities |
SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jim Beitel, MBA, has joined the company as its Chief Business Officer ("CBO"). Following recent transactions, Cidara is focused exclusively on advancing its Cloudbreak DFC pipeline, which provides numerous partnering and licensing opportunities, and a dedicated CBO will be a vital resource for the organization. Preetam Shah, Ph.D., MBA, who has held the roles of both Chief Fi
Dr. Davarpanah will lead Cidara's oncology efforts, focusing on strategy to advance development candidates Previously served as Clinical and Translational Lead in Oncology at Genentech/Roche SAN DIEGO, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the appointment of Nicole Davarpanah, M.D., J.D., as Senior Vice President of Translational Research & Development. In this position, Dr. Davarpanah will lead the company's oncology efforts
SAN DIEGO, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of Preetam Shah, Ph.D., MBA, as chief financial officer and chief business officer, and Shane Ward as chief legal officer and corporate secretary. "We are excited to welcome Preetam and Shane to Cidara's executive team," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "They are joining us during an exciting time in the Company's history, as we prepare for top-line data from the pivotal
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
4 - Cidara Therapeutics, Inc. (0001610618) (Issuer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
S-8 - Cidara Therapeutics, Inc. (0001610618) (Filer)
8-K - Cidara Therapeutics, Inc. (0001610618) (Filer)
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced a reduction in its workforce to focus on the clinical development of CD388, the Company's novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce. These strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating C
SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation details are as follows: Event: H.C. Wainwright 26th Annual Global ConferenceDate: Monday, September 9, 2024Time: 7:00 am ET Webcast: https://journey.ct.events/view/f994d8d6-20e4-4670-8752-ee2696bcf2e6 Cidara's
SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jim Beitel, MBA, has joined the company as its Chief Business Officer ("CBO"). Following recent transactions, Cidara is focused exclusively on advancing its Cloudbreak DFC pipeline, which provides numerous partnering and licensing opportunities, and a dedicated CBO will be a vital resource for the organization. Preetam Shah, Ph.D., MBA, who has held the roles of both Chief Fi
Cantor Fitzgerald analyst Louise Chen reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Overweight.
Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(0.20) by 1040 percent. The company reported quarterly sales of $8.46 million which beat the analyst consensus estimate of $6.30 million by 34.33 percent. This is a 67.44 percent decrease over sales of $25.99 million the same period last year.
- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sciences as well as BVF Partners and Canaan Partners to fund Phase 2b clinical trial - CD388, which is active against all strains of influenza A and B, is being developed for pre-exposure prophylactic treatment - Company to host business strategy update conference call and webcast today at 4:30 PM ET SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July 22, 2022, with an anticipated PDUFA target action date in the first quarter of 2023, if accepted for review following application validationMelinta acquires exclusive rights to commercialize rezafungin in the U.S.Cidara to receive up to $460 million, with an upfront cash payment of $30 million, $60 million in regulatory milestones, and up to $370 million in commercial milestones, plus tiered low double digits to mid-teens royalties on net salesCidara to focus on advancing Cloudbreak DFC platform in oncology and viral infections SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc
Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and
H.C. Wainwright upgraded Cidara Therapeutics from Neutral to Buy and set a new price target of $24.00
H.C. Wainwright resumed coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $6.00
Aegis Capital reiterated coverage of Cidara Therapeutics with a rating of Buy and set a new price target of $8.00 from $9.00 previously
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)
SC 13D - Cidara Therapeutics, Inc. (0001610618) (Subject)